NATIONAL INSTITUTES OF HEALTH

University of Oxford researchers have developed a programmable microcapsule delivery system that enables complete malaria vaccination in a single injection, eliminating the need for booster visits.

TAM Global has appointed Dr. Francesco Marincola, one of the world's most prolific tumor immunologists with over 700 peer-reviewed publications, as Chief Scientific Officer across its expanding healthcare platform.

The FDA approved nitisinone (Harliku) as the first and only treatment for alkaptonuria, a rare genetic metabolic disorder affecting 1 in 250,000 to 1 million Americans.

The FDA announced an immediate review of clinical trials that send American citizens' living cells to China and other hostile countries for genetic engineering, often without patient knowledge or consent.

Bavarian Nordic announced the sale of its Priority Review Voucher for $160 million, awarded following FDA approval of its chikungunya vaccine VIMKUNYA in February 2025.

Astrocyte Pharmaceuticals has dosed the first patient in its Phase 2 STARFAST trial testing AST-004, the first drug to demonstrate neuroprotective effects against concussion in preclinical studies.

BBOT published preclinical data in Science demonstrating that BBO-10203, a first-in-class oral inhibitor, effectively blocks RAS-PI3Kα interaction without inducing hyperglycemia across multiple tumor types.

Health Secretary Robert F. Kennedy Jr. has replaced all 17 members of the CDC's Advisory Committee on Immunization Practices with eight new appointees, significantly downsizing the committee.

University at Buffalo researchers have developed a lipidated peptide molecule that provides chronic pain relief for up to three weeks with a single local injection, targeting the Magi-1/NaV1.8 protein interaction.

Dr. Elizabeth Mittendorf, the 2026-2027 ASCO President-Elect, will focus on advancing multidisciplinary collaboration, broadening clinical trial access, and strengthening oncology workforce support during her presidency.